Metabolomics for predicting fetal growth restriction: protocol for a systematic review and meta-analysis

Debora Farias Batista Leite,1,2 Aude-Claire Morillon,3 Elias F Melo Júnior,1 Renato T Souza,2 Ali S Khashan,3,4 Philip N Baker,5 Louise C Kenny,3,6 José Guilherme Cecatti2

ABSTRACT

Introduction Fetal growth restriction (FGR) is a relevant research and clinical concern since it is related to higher risks of adverse outcomes at any period of life. Current predictive tools in pregnancy (clinical factors, ultrasound scan, placenta-related biomarkers) fail to identify the true growth-restricted fetus. However, technologies based on metabolomics have generated interesting findings and seem promising. In this systematic review, we will address diagnostic accuracy of metabolomics analyses in predicting FGR.

Methods and analysis Our primary outcome is small for gestational age infant, as a surrogate for FGR, defined as birth weight below the 10th centile by customised or population-based curves for gestational age. A detailed systematic literature search will be carried in electronic databases and conference abstracts, using the keywords ‘fetal growth retardation’, ‘metabolomics’, ‘pregnancy’ and ‘screening’ (and their variations). We will include original peer-reviewed articles published from 1998 to 2018, involving pregnancies of fetuses without congenital malformations; sample collection must have been performed before clinical recognition of growth impairment. If additional information is required, authors will be contacted. Reviews, case reports, cross-sectional studies, non-human research and commentaries papers will be excluded. Sample characteristics and the diagnostic accuracy data will be retrieved and analysed. If data allows, we will perform a meta-analysis.

Ethics and dissemination As this is a systematic review, no ethical approval is necessary. This protocol will be publicised in our institutional websites and results will be submitted for publication in a peer-reviewed journal.

PROSPERO registration number CRD42018089985.

INTRODUCTION

Fetal growth restriction (FGR) is usually defined as a fetus that has not reached its intrauterine growth potential,1 2 with no major congenital abnormalities1 and has also been named as fetal growth retardation, intrauterine growth restriction or retardation.3 This heterogeneous condition is associated with increased risks of stillbirth,4 5 neonatal intensive care unit admission,6 7 neonatal mortality,8 cognitive and behavioural impairment in infancy7 and chronic non-transmissible disease in adulthood.8 9 FGR is mainly diagnosed according to the estimated fetal weight in ultrasound scans below the 10th centile,2 9 although it is anticipated that misdiagnosis can occur: fetuses below the 10th centile, but with normal outcomes (‘constitutionally small’), or fetuses above the 10th centile, but who did not follow personal growth potential.2 9 In this context, antenatal recognition of truly restricted fetuses, that is, those at higher risk of morbidity and mortality in any period of life, followed by adequate obstetrical care, can improve neonatal outcomes.10

Unfortunately, in current practice, there is no gold standard for FGR diagnosis. Recent consensus has added ultrasound criteria (eg, abdominal circumference, umbilical and uterine artery Doppler measurements) and lowered estimated fetal weight cut-offs (<3rd centile)1 to improve specificity. In these terms, the concept of FGR can overlap with that of small for gestational age (SGA), which includes infants with birth weight below the 10th (or fifth, or third) centile for gender and gestational age.11 In fact, it is common to use SGA as a surrogate for FGR,6 12 13 as an indication of real intrauterine growth impairment. Besides that, neonatal parameters seem more
adequate as ‘patient important outcomes’, but regrettably, ultrasound have still low accuracy to determine them.  

Since 1990s, when the thrifty phenotype theory was introduced, a huge effort has been undertaken to investigate the pathologically growth restricted fetuses and newborns and to enhance antenatal screening. Clinical data has been intensively studied, with conflicting risk factors and, in general, poor accuracy is achieved for identifying impaired birth weight or neonatal morbidity, even when first, second or third trimester ultrasound parameters are added to prediction model. Using only clinical or ultrasound variables, the great majority of SGA babies will only be recognised after birth, by population-based or customised curves. Biomarkers, such as placental growth factor (PIGF), soluble fms-like tyrosine kinase 1 (s-Flt-1) and alpha-fetoprotein, have each been found to show promise as aids to understanding FGR. However, the performance of these angiogenic factors as predictors of FGR has been limited (positive likelihood ratio, LR+, of 1.3 for PIGF and 1.4 for s-Flt-1). Similarly, placental proteins are not robust enough biomarkers for FGR (eg. LR+ of 3.7 for placental protein-13 in first trimester). Therefore, there is a real need for better methods of FGR prediction.

The disappointing evidence may be due to the multifactorial nature of FGR; the aetiology of the condition is complex and poorly defined. Moreover, placental structure and functioning, maternal and fetal metabolism vary during pregnancy. In this context, contemporary metabolomics approaches have identified several pathways and metabolic processes that may contribute to FGR, such as disruptions in DNA methylation, cellular signalling, neurotransmitter precursors and energy generation.

Despite excellent performance of some metabolites in predicting FGR (area under the curve, above 0.9), these studies have shown an overall modest accuracy. However, only two ‘omics’ studies were included in Conde-Agudelo et al review, and issues related to gestational age of sampling and delivery, or analysis of composite outcomes, could have introduced bias and confounders to metabolomics findings. In recent years, many authors have applied diverse metabolomics techniques to predict FGR, suggesting that metabolite biomarkers may have a role to play in disease screening. Thus, the main objective of this systematic review is to define the accuracy of metabolomics techniques for predicting FGR. As secondary aims, we will try to determine which metabolites are robust candidates for a prediction model of FGR and which chemical class they belong to.

METHODS AND ANALYSIS

Review question
What is the accuracy of metabolomics for predicting FGR?
the last 20 years (1998–2018). The preliminary searches for this systematic review have started in February 2018. The search strategy will be re-run before final analysis, to check for recently published eligible studies. There are no language restrictions.

**Data extraction and management**

All searches will be exported to a reference manager (EndNote). Individually, two researchers (DFBL and ACM) will select papers according to (1) title or abstract and (2) full text, that will be read only when abstracts are not sufficient to decide about inclusion criteria. Any disagreement about selected studies will be dealt by a third researcher (EFMJ or RTS); in these cases, only after majority decision (2:1 ratio) the next step will be performed. A fifth investigator (JGC) will revise all procedures before approving the data extraction. DFBL, ACM and LCK will deal with the statistic procedures. JGC, PNB and LCK will re-examine all steps and supervise data interpretation.

A standardised form will be applied to extract the variables of interest—by two independent researchers—which will include: authors and year of publication, country of participants’ enrolment, study design, definition used for FGR/SGA (customised or population-based charts) and outcome measured, number of affected (who later delivered a FGR/SGA baby) and non-affected pregnant women, gestational age of assessment (throughout pregnancy), laboratory methods and biological sample analysed (eg, blood, amniotic fluid). In addition, data regarding growth impairment suspicion in pregnancy—such as gestational age, criteria applied for diagnosis and follow-up—will be retrieved once available. Researchers will contact authors (by electronic address) if any clarification of data is needed. The metabolites described will be matched with the Human Metabolome database to check their characteristics.

**Strategy for data synthesis**

Details about data search and selection will be presented as a flow diagram, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommendations. An aggregate participant data synthesis will be performed with all included studies; narrative data will be analysed and structured according to birth weight centile (10th, 5th and 3rd) and curve type (population-based or customised curves). Additionally, the metabolites will be grouped and synthesised according to their biological function and chemical subclass. Studies’ characteristics and risk of bias assessment will be demonstrated in tables. Once possible, we will perform subgroup analysis according to:

- Which metabolomic methods were applied (gas or liquid chromatography coupled with mass spectrometry; or proton nuclear magnetic resonance).
- Maternal health status before pregnancy (healthy ones vs women with any chronic health condition).
- Gestational age of first fetal growth impairment suspicion (early vs late FGR).
- Type of pregnancy (single vs multiple).

Depending on data availability, accuracy measures will be calculated and a meta-analysis will be drawn. Considering the quantitative nature of the metabolomics approach and the expected different thresholds for metabolites in each study, we will try to perform the hierarchical summary receiver characteristic operating curve. Heterogeneity will also be assessed, through I² test.

**Risk of bias assessment**

Both investigators initially involved with literature search (DFBL and ACM) will assess methodological quality and applicability of all included studies, and they must check their judgements. A third researcher (EFMJ or RTS) will resolve any disagreement if necessary and the final decisions will be made by majority. We will use the ‘Quality Assessment of Diagnostic Accuracy Studies’ tool, which comprised four domains: patient selection, characteristics of index test (metabolomics technique), the reference standard test (measurement of birth weight) and flow and timing of patient inclusion and follow-up. Every study will be labelled as ‘low’, ‘high’ or ‘unclear’ risk of bias for each domain. For example, there is ‘low risk of bias’ if the study clearly states how the metabolomics techniques were performed, or which birth weight curve was applied to identify the SGA babies.

Regarding publication bias, we will assess the symmetry of funnel plots if more than ten studies are included in the meta-analysis.

**Potential limitations to this review**

Concerning the publication bias, we expect to encounter more published positive results and data interpretation must take this issue in consideration. The metabolomics approach is highly detailed and meticulous, has shown great technological advancements in recent years, and results from mass spectrometry and from nuclear magnetic resonance complement each other. Therefore, we acknowledge that we may find distinct metabolites in each study and generalisation may be challenging.

In this systematic review, we have considered SGA as a proxy for FGR, as other authors. The consensus for FGR diagnosis was published recently and past investigations may have used distinct terminology or conflicting criteria for this condition in pregnancy. Additional confounders to interpret the selected studies will include clinical factors potentially associated to FGR/SGA, like parity, smoking habits and history of previous fetal growth impairment. These characteristics will be appraised during data extraction and synthesis, and detailed evidence will be retrieved.

**Ethics and dissemination**

This protocol follows the PRISMA Protocols statements. A report of this systematic review will be sent to our
sponsors. This protocol will be electronically available on UNICAMP-CNpq-Gates Foundation project website (www.medsclinet.com/samba) and Infant Centre website (infantcentre.ie). Our results will be submitted to publication in peer-reviewed journals.

**Patient and public involvement**

Patients and or public were not involved at all in elaborating this systematic review protocol.

**CONCLUSION**

This systematic review will synthesise data about metabolomics and FGR/SGA, a promising field for understanding disease pathophysiology and natural history. By highlighting the metabolites and chemical classes that they belong to, this review might present solid data to future research protocols, that can target the most promising compounds, or assess the participants in a more reliable gestational age, for example. A robust FGR/SGA prediction assumption greats importance in reproductive health and epidemiology, since this condition is associated with short and long-term adverse outcomes for the offspring.

**Author affiliations**

1. Department of Maternal and Child Health, Clinics Hospital of Federal University of Pernambuco, Recife, Brazil
2. Department of Gynaecology and Obstetrics, University Campinas, Sao Paulo, Brazil
3. Irish Centre for Fetal and Neonatal Translational Research (INFANT), University College Cork, Cork, Ireland
4. School of Public Health, University College Cork, Cork, Ireland
5. College of Life Sciences, University of Leicester, Leicester, UK
6. Department of Women’s and Children’s Health, Faculty of Health and Life Sciences, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

**Acknowledgements**

We would like to thank Shauna Barret, librarian of Brookfield Library, University College Cork, Ireland, for her support with the literature search strategy. We are also grateful to Mave O’Connell, for her suggestions to the final manuscript.

**Contributors**

DFBL (the guarantor of the review) and A-CM developed the systematic review protocol and will perform the literature search, study selection, data extraction and risk of bias assessment. ASK, PNB, RTS, EFJM and JGC supervised protocol elaboration and the latter three will resolve any discrepancy about methodology. ASK, DFB and A-CM will deal with statistics procedures. PNB and LCX performed the last amendments of protocol and will revise the final systematic review draft. All authors have read this manuscript and have agreed with this submission.

**Funding**

This research was supported by Brazilian National Research Council (grant number 401636/2013-5) and Bill and Melinda Gates Foundation (grant number OPP1107597-Grand Challenges Brazil: Reducing the burden of preterm birth, Flotec number 05/2013), which provided funding to PRETERM-SAMBA project (www.medsclinet.com/samba). DFB was granted a scholarship (process number 88881.134512/2016-01) from the Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES) and developed part of her doctoral studies as a visiting student at University College Cork, Ireland. RTS has also awarded a scholarship from CAPES (process number 88881.134095/2016-01). A-CM was granted a scholarship from Science Foundation Ireland, for her doctoral thesis. Our sponsors have not intervened in authors’ decision to write the systematic review protocol or to submit this paper.

**Competing interests**

DFBL and A-CM are studying this technology in predicting FGR. JGC, LCX and PNB have presented conference talks about this field. LCX and PNB are principal investigators of Metabolomic Diagnostics.

**Patient consent**

Not required.

**Ethics approval**

As this is a systematic review protocol, no ethics committee approval is necessary.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the license is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**REFERENCES**


